All XRAYs
Relevance: Medium-High
Most relevant for: Women diagnosed with early stage (1-3) breast cancer
Study: Weight gain associated with breast cancer survivorship
Weight gain in breast cancer survivors can affect survival and quality-of-life. This study found that breast cancer survivors are more likely to gain weight than women of the same age who are at high risk, but have never been diagnosed with cancer. The study looked at which groups of survivors were more likely to gain weight. (8/24/15)
READ MORE ›
Relevance: Medium-High
Most relevant for: Bahamanian women
Study: Prevalence of BRCA mutations in Bahamian women
The Bahamas has the highest known frequency of BRCA mutations among people diagnosed with breast cancer. This study reviewed whether population-based BRCA testing (testing everyone regardless of family or personal history of cancer) would be an effective approach for finding mutation carriers in the Bahamas. (3/4/19)
READ MORE ›
Relevance: High
Most relevant for: People with metastatic, hormone-positive, Her2-negative breast cancer
Study: CDK inhibitors may increase survival for ER-positive metastatic breast cancer patients
The phase III MONALEESA-7 study is a clinical trial looking at the effect of a type of treatment known as a CDK4/6 inhibitor in pre- or perimenopausal women with hormone receptor–positive advanced breast cancer. (7/22/19)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with metastatic, triple-negative breast cancer
Study: FDA approves an immunotherapy treatment for some patients with triple-negative breast cancer
The FDA approved the use of the immunotherapy drug atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for certain patients with advanced triple-negative breast cancer. (5/26/19)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with metastatic, triple-negative breast cancer
Study: Smart drug shows promising results for treatment of metastatic triple-negative breast cancer
We report results of an early-stage clinical trial of a new class of drugs for metastatic triple-negative breast cancer (TNBC). IMMU-132 is an antibody-drug conjugate, meaning that it combines two different molecules: an antibody that targets certain tumor proteins and delivers SN-38, a chemotherapy drug that can kill tumor cells. This study looks at whether IMMU-132 is safe and effective for treating metastatic TNBC. (4/16/19)
READ MORE ›